As the eighth China International Import Expo (CIIE) kicked off in Shanghai on Nov 5, Boston Scientific, a US medical device provider, showcased over 80 innovations in cardiology, peripheral vascular, oncology, and other fields, including six new launches.

Among the innovations, two debut products address critical clinical needs. The Orbera365 Intragastric Balloon System, designed for reversible weight loss procedures, fills a gap in China's endoscopic bariatric treatment landscape.

The Orbera365 Intragastric Balloon System makes its debut at the ongoing eighth CIIE. [Photo/Boston Scientific]

The Intera 3000 Hepatic Artery Infusion (HAI) Pump, the only US Food and Drug Administration-approved implantable pump for HAI therapy, provides therapies for patients with colorectal liver metastases and intrahepatic cholangiocarcinoma.

The Intera 3000 Hepatic Artery Infusion (HAI) Pump. [Photo/Boston Scientific]

To better communicate cutting-edge health concepts to a broader audience, Boston Scientific incorporated thoughtful design elements and smart technologies throughout its booth, transforming complex medical concepts into accessible visual and interactive experiences.

Boston Scientific's booth at the eighth CIIE. [Photo/IC]

In October 2024, Boston Scientific completed construction on its factory in Shanghai's Lin-gang Special Area, marking the company's first manufacturing base in China. The facility has produced four product prototypes, with type testing and clinical reports all completed. Mass production is expected to commence in 2026.

The medical technology leader has already signed up for the ninth edition of the CIIE.